1. Introduction

Athletic enhancement biotechnology legalization concerns the legal, ethical, medical and sporting questions arising when biotechnology is used to improve athletic performance beyond ordinary training, nutrition and rehabilitation.

Traditional performance enhancement includes anabolic steroids, stimulants and certain hormones. Emerging biotechnology creates more complex questions involving gene editing, gene therapy, cell-based treatments, regenerative medicine, biological implants and technologies designed to modify muscle growth, oxygen delivery, endurance or recovery.

The central legal debate is whether these interventions should remain prohibited in competitive sport, be permitted under carefully controlled conditions, or be allowed in selected circumstances with medical supervision and informed consent.

There is no single international law that comprehensively legalizes or prohibits every form of athletic enhancement biotechnology. The position depends on the particular intervention, applicable anti-doping rules, medical regulations, national law and competition rules.

Important legal distinction: A treatment can be lawful in ordinary medical practice but prohibited in sport. Conversely, a substance's absence from a prohibited list does not automatically establish that it is safe, approved for human use or permitted by a particular sporting organization.

2. Meaning and scope

Athletic enhancement biotechnology can be divided into five categories.

1. Genetic enhancement

Altering genes or gene expression to influence muscle development, endurance, oxygen utilization or recovery. Gene doping is a particular concern because genetic interventions may be difficult to detect using conventional drug tests.

2. Cell-based and regenerative therapies

Stem-cell treatments, tissue engineering and biological interventions intended to repair injury or improve recovery. The legal analysis often turns on whether the treatment is genuinely therapeutic or is being used for prohibited enhancement.

3. Biological and hormonal enhancement

Interventions affecting hormones, red blood cell production, oxygen transport or metabolic pathways. These may overlap with existing anti-doping prohibitions.

4. Bioengineered devices and implants

Advanced prostheses, biological implants and engineered tissues raise questions about disability rights, technical advantages, eligibility classifications and whether a device provides an unfair competitive advantage.

5. Precision and personalized enhancement

Genetic profiling, biological monitoring and individualized medical interventions. These create additional concerns about privacy, discrimination, consent and commercial exploitation.

These categories should not be treated identically. Restoring an athlete's injured tissue is legally and ethically different from modifying healthy tissue solely to obtain a competitive advantage.

3. Existing international legal framework

A. World Anti-Doping Code

The World Anti-Doping Agency (WADA) administers the international anti-doping framework through the World Anti-Doping Code, the Prohibited List and related international standards.

Under the Code, an anti-doping rule violation can arise from prohibited substances or methods, subject to the applicable rules and evidence. Athletes may also face consequences for certain violations involving possession, administration, trafficking or other prohibited conduct.

Gene doping and certain cell-related or gene-related enhancement methods fall within the anti-doping framework. The precise classification depends on the current Prohibited List and applicable definitions.

The policy objectives include:

Protecting athletes from health risks.

Preserving fair competition and the integrity of sporting results.

Preventing coercion to use risky enhancement technologies.

Establishing common rules across international competitions.

Providing procedures for testing, hearings, appeals and sanctions.

The framework also allows therapeutic use exemptions (TUEs) in qualifying circumstances. A TUE is not a general permission to enhance performance: it is an exception subject to medical and regulatory criteria.

B. UNESCO International Convention against Doping in Sport

The UNESCO International Convention against Doping in Sport supports international cooperation against doping. States implement their obligations through domestic legal and administrative arrangements.

The Convention does not independently establish a universal licensing system for all future enhancement biotechnology. Instead, it supports coordinated anti-doping policies, education, research and enforcement.

C. India's anti-doping framework

India's principal statutory framework includes the National Anti-Doping Act, 2022, alongside applicable rules and anti-doping policies administered by the National Anti-Doping Agency (NADA).

NADA's responsibilities include testing, results management, anti-doping education and implementation of relevant anti-doping rules. Indian athletes competing internationally may also be subject to the rules of their international federations and the World Anti-Doping Code.

Government of India

+1

Consequently, a biotechnology intervention cannot be assumed permissible simply because it is prescribed by a doctor or obtained legally in India.

4. Major legalization debates

A. Argument in favour of legalization

Supporters argue that carefully regulated enhancement biotechnology may be justified under specific conditions.

1. Individual autonomy and bodily freedom

Competent adults generally have significant freedom to make medical decisions about their own bodies. Supporters argue that athletes should not automatically be denied access to a treatment merely because it improves physical performance.

However, sporting organizations can impose eligibility rules, and personal consent does not eliminate the risk of coercion, medical harm or unfair competition.

2. Medical innovation

Some technologies initially developed for treating disease or injury may later have performance-related applications. Regulated access could promote clinical research, improve rehabilitation and establish reliable safety standards.

3. Equal access through regulation

Supporters contend that prohibition alone may push enhancement into unregulated markets. A licensing system could theoretically establish medical supervision, disclosure requirements and enforceable safety standards.

The counterargument is that regulated access might still favour wealthy athletes and teams with superior medical facilities.

4. Freedom of competition

Some proponents believe sport should allow a broader range of human capabilities and technological innovation. Under this view, the relevant question is not whether an intervention improves performance, but whether it is sufficiently safe, transparent and available under fair rules.

This proposal would require sporting bodies to reconsider the objectives of each competition and determine which forms of enhancement are compatible with them.

B. Argument against legalization

1. Health and safety

Genetic modification, unapproved cell therapies and experimental biological interventions may carry uncertain or irreversible risks. Consent alone cannot establish that a procedure is safe.

Risks may include immune reactions, unintended genetic effects, abnormal tissue growth and delayed complications, depending on the intervention.

2. Competitive equality

If enhancement becomes expensive or technologically complex, well-funded athletes could gain advantages unavailable to others. Legalization might therefore increase inequality rather than eliminate it.

3. Coercion

Even where enhancement is formally voluntary, athletes may feel compelled to undergo it to remain competitive. This is particularly concerning for young athletes, economically dependent athletes and those whose careers depend on selection.

4. The integrity of sport

Sporting organizations may define legitimate achievement by reference to training, natural ability, tactical skill and permitted equipment. They may reasonably conclude that certain biological interventions conflict with the identity of their sport.

5. Difficulties in detection

Genetic and cellular interventions may not produce the same detectable markers as conventional drugs. Effective enforcement may require new laboratory techniques, long-term biological monitoring and careful rules concerning genetic information.

These concerns are reflected in the current international prohibition of gene and cell doping.

Athletics Integrity Unit

+1

5. Important case laws

There is no widely established body of judicial decisions specifically holding that athletic gene editing should be legalized. The following cases are nevertheless important because they address the legal principles that would govern such a debate.

Case 1: Oscar Pistorius v. IAAF

Court of Arbitration for Sport (CAS), CAS 2008/A/1480, award of 16 May 2008.

Facts: Oscar Pistorius, a double below-knee amputee, used carbon-fibre prosthetic limbs and sought to compete in athletics competitions against athletes without disabilities. The international athletics federation had excluded him after concluding that his prostheses provided a competitive advantage.

Decision: CAS set aside the exclusion because the federation had not established the claimed net advantage to the required standard of proof. The ruling applied to Pistorius and the specific prostheses examined; it was not a blanket approval of all prosthetic technologies.

Jurisprudence TAS/CAS

+1

Legal principles:

Eligibility restrictions should be supported by appropriate evidence.

Scientific uncertainty matters when determining whether a technology confers an unfair advantage.

Decisions should be based on the particular athlete, device and applicable rules.

Sporting regulators must apply their rules fairly and rationally.

Relevance to biotechnology legalization: If an athlete uses a novel bioengineered implant, genetic intervention or other performance-related technology, this case illustrates the importance of evidence and the need to distinguish a proven competitive advantage from speculation.

However, the case does not mean that every technology must be permitted until its dangers are conclusively established. Anti-doping rules may prohibit specified methods independently of a case-specific finding of advantage.

Case 2: Caster Semenya v. IAAF

CAS 2018/O/5794 and CAS 2018/O/5798, award of 30 April 2019.

Facts: Caster Semenya and Athletics South Africa challenged athletics regulations concerning eligibility for certain women's events based on specified differences of sex development and testosterone-related criteria.

Decision: The CAS majority upheld the challenged regulations as necessary, reasonable and proportionate to the federation's objectives, while acknowledging their discriminatory effects and concerns about practical application. The Swiss Federal Supreme Court subsequently dismissed Semenya's appeal against the CAS award in 2020. Later proceedings before the European Court of Human Rights raised separate questions about effective judicial protection and discrimination.

Jus Mundi

+1

Legal principles:

Fair competition may be a legitimate regulatory objective.

Scientific evidence and proportionality are important when restricting eligibility.

Medical interventions imposed as a condition of participation can raise serious rights concerns.

The pursuit of competitive equality must be examined alongside dignity, bodily autonomy and non-discrimination.

Relevance to biotechnology legalization: The case demonstrates that biological characteristics and sporting eligibility cannot be resolved solely by asking whether a physiological trait affects performance. Regulators must also consider the legal basis, evidence, effects and proportionality of their rules.

The case concerned sex eligibility regulations, not genetic enhancement or gene doping. It should therefore be used by analogy rather than treated as a direct precedent on biotechnology legalization.

Case 3: Semenya v. Switzerland

European Court of Human Rights, Grand Chamber judgment, 10 July 2025.

The European Court of Human Rights examined Semenya's complaint concerning the Swiss courts' review of her challenge to the athletics regulations.

The Grand Chamber found a violation of Article 6 § 1 of the European Convention on Human Rights concerning the procedural protection afforded in the Swiss proceedings. The judgment is significant because it addresses the need for effective judicial scrutiny of sporting arbitration when important rights are at stake.

HUDOC

Relevance to biotechnology legalization: A sporting body should not necessarily be the final and unreviewable authority on complex scientific eligibility questions. Where applicable law permits judicial review, courts may need to examine whether arbitration and related proceedings provide adequate procedural safeguards.

The judgment does not create a general right to use performance-enhancing biotechnology.

Case 4: Meca-Medina and Majcen v. Commission

Court of Justice of the European Union, Case C-519/04 P, judgment of 18 July 2006.

Facts: Two professional swimmers challenged anti-doping measures under European Union competition law.

Decision: The Court held that anti-doping rules are not automatically exempt from competition-law scrutiny simply because they concern sport. Their compatibility with EU competition law must be assessed in light of their objectives and context, including whether restrictive effects are inherent in and proportionate to legitimate objectives.

Legal principles:

Sporting autonomy is not unlimited.

Anti-doping rules may be subject to competition-law review.

The legitimate objective of fair competition is relevant to the proportionality analysis.

Relevance to biotechnology legalization: An athlete or biotechnology company might argue that a prohibition restricts professional opportunities or commercial activity. Meca-Medina shows why the legal analysis must examine the purpose and proportionality of the particular rule rather than assuming either that all restrictions are valid or that every restriction is unlawful.

This is a European competition-law case, not a ruling that doping should be legalized.

6. Comparative legal position

India's NADA framework and the current international Prohibited List are important starting points for an Indian athlete or sports organization.

Government of India

+1

7. Regulatory models for possible legalization

There are several theoretical models for regulating athletic enhancement biotechnology.

Model 1

Continued prohibition

Maintain prohibitions on enhancement methods that meet the applicable anti-doping criteria. Permit legitimate medical treatment through established therapeutic use exemption procedures where eligible.

Model 2

Conditional medical authorization

Permit selected interventions only after appropriate clinical approval, independent safety assessment and sporting authorization. A medical regulator's approval would not itself override sporting prohibitions.

Model 3

Separate enhanced competitions

Create competitions with distinct eligibility rules for certain forms of enhancement. This would still require decisions about safety, athlete consent, access, liability and the protection of minors.

Model 4

Intervention-specific regulation

Assess each technology individually according to its medical purpose, risks, reversibility, effectiveness, detectability and effect on competition.

Of these approaches, an intervention-specific system provides a useful framework for legal analysis because different technologies present very different risks. It is a proposed regulatory model, not a description of a universal system currently in force.

8. Constitutional and human-rights issues

A. Bodily autonomy

An athlete may argue that restrictions interfere with personal liberty and medical decision-making. The counterargument is that participation in organized competition is subject to eligibility rules designed to protect athletes and the integrity of the event.

The legal question is whether the restriction has a valid basis and is proportionate under the law that applies.

B. Equality and non-discrimination

Rules governing biological enhancement may affect athletes differently because of disability, genetic characteristics, sex-related traits or access to medical treatment.

Regulators should explain why distinctions are necessary, use reliable evidence and consider whether less restrictive alternatives are available.

C. Privacy and genetic information

Genetic testing can reveal information extending beyond sporting performance, including information about biological relatives. A lawful system should define what data may be collected, who can access it, how long it may be retained and whether it may be used for other purposes.

D. Informed consent and minors

Young athletes may not fully understand long-term risks or feel able to refuse an intervention recommended by a coach or sponsor. Special safeguards are therefore necessary when minors are involved.

Consent should be voluntary and informed, but it does not automatically make an unsafe or prohibited intervention lawful.

E. State responsibility and judicial review

Public authorities and sporting organizations may have different legal obligations. Depending on the jurisdiction, a decision may be subject to administrative review, constitutional scrutiny, arbitration or ordinary judicial proceedings.

The relevant case law will depend on the regulator's legal status and the rights involved.

9. Biotechnology companies, sponsors and liability

Legalization debates also concern the organizations that develop, market, administer or finance enhancement interventions.

Potential liability issues include:

Product liability: injury caused by a defective or inadequately warned-about product.

Medical negligence: failure to meet the applicable standard of clinical care.

Misleading advertising: unsupported claims about safety, performance or regulatory approval.

Contractual liability: disputes over eligibility clauses, sponsorship termination and representations about an athlete's compliance.

Research ethics: inadequate consent, improper clinical experimentation or failure to protect research participants.

Data protection: misuse or unauthorized disclosure of genetic and health information.

A biotechnology company cannot assume that a product is suitable for competitive athletes merely because it has a legitimate therapeutic application. Likewise, an athlete's acceptance of sponsorship terms does not necessarily waive statutory protections.

10. Scientific uncertainty and the burden of proof

Scientific uncertainty is central to the legalization debate. Regulators must distinguish between:

Evidence that an intervention produces a performance effect.

Evidence that it poses an actual or potential health risk.

Evidence that it compromises the objectives of a particular sport.

Evidence sufficient to justify a specific prohibition or sanction.

Under the anti-doping framework, the Prohibited List is reviewed periodically, and its criteria include potential performance enhancement, health risk and conflict with the spirit of sport.

Athletics Integrity Unit

+1

These considerations raise two different questions.

Regulatory question: Is there sufficient evidence to prohibit an intervention prospectively?

Adjudicative question: Has a particular athlete committed a violation under the applicable rules and standard of proof?

The answers need not be identical. A regulator may prohibit a method because of its potential risks, while a disciplinary tribunal must still determine whether the athlete's conduct falls within the rule and whether the violation has been established.

11. Future legal developments

The principal areas likely to require continuing legal attention include:

More sophisticated methods for detecting gene and cell doping.

Rules addressing interventions that persist after treatment has ended.

Clear distinctions between rehabilitation and non-therapeutic enhancement.

International cooperation concerning unapproved biological products.

Standards for scientific evidence and expert testimony.

Protection of athletes against coercive enhancement practices.

Procedures for challenging eligibility and anti-doping decisions.

Harmonization of sporting rules with medical and human-rights law.

A significant near-term development is the 2027 World Anti-Doping Code, scheduled to take effect on 1 January 2027. The reforms include changes concerning athlete rights, procedural fairness, proportionality and protection of minors. These reforms do not themselves amount to general legalization of enhancement biotechnology.

Sport Integrity Australia

+1

12. Conclusion

Athletic enhancement biotechnology legalization is a conflict between competing legal values: personal autonomy, scientific progress, public health, equality, fair competition and the integrity of sport.

The relevant case law establishes several useful principles. Pistorius highlights evidence-based decisions about technological advantage; Semenya illustrates the conflict between sporting objectives and individual rights; and Meca-Medina confirms that sporting restrictions can be subject to legal scrutiny.

None of these cases establishes a general right to use gene editing, genetic enhancement or other prohibited performance-enhancing methods.

A comprehensive legal approach should distinguish therapeutic treatment from enhancement, require sound scientific evidence, protect athletes from coercion, provide fair procedures and ensure that any proposed authorization complies with applicable medical and sporting law.

Ultimately, legalizing a biotechnology for medical use, permitting it in competitive sport and establishing that it is safe are three separate legal questions. A sound regulatory framework must answer each one independently.